Combined itraconazole-pentoxifylline treatment promptly reduces lung fibrosis induced by chronic pulmonary paracoccidioidomycosis in mice

Pulmonary Pharmacology and Therapeutics

Volumn 24, Issue 1, 2011, Pages 81-91

  Naranjo, Tonny W ^a,b   Lopera, Damaris E ^a   Diaz Granados, Lucy R ^b   Duque, Jhon J ^c   Restrepo M, Angela ^a   Cano, Luz E ^a,c  

^a Unidad de Biología Celular y Molecular   (Colombia)

^b UNIVERSIDAD PONTIFICIA BOLIVARIANA   (Colombia)

^c UNIVERSIDAD DE ANTIOQUIA   (Colombia)

Author keywords

Cytokines; Itraconazole; Lung fibrosis; Paracoccidioides brasiliensis; Paracoccidioidomycosis; Pentoxifylline

Indexed keywords

FISOPRED; GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 1BETA; ITRACONAZOLE; P 1784; PENTOXIFYLLINE; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG EFFICACY; HISTOPATHOLOGY; IN VITRO STUDY; LIVER; LUNG; LUNG FIBROSIS; LUNG INFECTION; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PARACOCCIDIOIDES BRASILIENSIS; PRIORITY JOURNAL; SKIN; SOUTH AMERICAN BLASTOMYCOSIS;

ANIMALS; ANTIFUNGAL AGENTS; COLLAGEN; CYTOKINES; DRUG THERAPY, COMBINATION; IMMUNOLOGIC FACTORS; ITRACONAZOLE; LUNG; LUNG DISEASES, FUNGAL; MALE; MICE; MICE, INBRED BALB C; PARACOCCIDIOIDES; PARACOCCIDIOIDOMYCOSIS; PENTOXIFYLLINE; PULMONARY FIBROSIS; RETICULIN;

EID: 79251539282     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2010.09.005     Document Type: Article

References (50)

1. Matute D.R., Quesada-Ocampo L.M., Rauscher J.T., McEwen J.G. Evidence for positive selection in putative virulence factors within the Paracoccidioides brasiliensis species complex. PLoS Negl Trop Dis 2008, 17(2(9)):e296.
2. Bagagli E., Theodoro R.C., Bosco S.M., McEwen J.G. Paracoccidioides brasiliensis: phylogenetic and ecological aspects. Mycopathologia 2008, 165(4-5):197-207.
3. Borges-Walmsley M.I., Chen D., Shu X., Walmsley A.R. The pathobiology of Paracoccidioides brasiliensis. Trends Microbiol 2002, 10(2):80-87.
4. Franco M., Montenegro M.R., Mendes R.P., Marques S.A., Dillon N.L., Mota N.G. Paracoccidioidomycosis: a recently proposed classification of its clinical forms. Rev Soc Bras Med Trop 1987, 20(2):129-132.
5. Mamoni R.L., Blotta M.H. Kinetics of cytokines and chemokines gene expression distinguishes Paracoccidioides brasiliensis infection from disease. Cytokine 2005, 32:20-29.
6. Silva S.S., Paes H.C., Soares S.M., Fernandes L., Felipe M.S. Insights into the pathobiology of Paracoccidioides brasiliensis from transcriptome analysis advances and perspectives. Mycopathologia 2008, 165(4-5):249-258.
7. Brummer E., Castañeda E., Restrepo A. Paracoccidioidomycosis: an Update. Clin Microbiol Rev 1993, 6:89-117.
8. Restrepo S., Tobón A., Trujillo J., Restrepo A. Development of pulmonary fibrosis in mice during infection with Paracoccidioides brasiliensis conidia. J Med Vet Mycol 1992, 30(3):173-184.
9. Menezes V.M., Soares B., Fontes C. Drugs for treating paracoccidioidomycosis. Cochrane Database Syst Rev 2006, 19(2):CD004967.
10. Queiroz-Telles F., Goldani L.Z., Schlamm H.T., Goodrich J.M., Espinel-Ingroff A., Shikanai-Yasuda M.A. An open-label comparative pilot study of oral voriconazole and itraconazole for long-term treatment of paracoccidioidomycosis. Clin Infect Dis 2007, 45(11):1462-1469.
11. De Beule K., Van Gestel J. Pharmacology of itraconazole. Drugs 2001, 61:27-37.
12. Khan Z.K., Jain P. Antifungal agents and immunomodulators in systemic mycoses. Ind J Chest Dis Allied Sci 2000, 242(4):345-355.
13. Tobón A.M., Agudelo C.A., Osorio M.L., Alvarez D.L., Arango M., Cano L.E., et al. Residual pulmonary abnormalities in adult patients with chronic paracoccidioidomycosis: prolonged follow-up after itraconazole therapy. Clin Infect Dis 2003, 37(7):898-904.
14. Noel P., Nelson S., Bokulic R., Bagby G., Lippton H., Lipscomb G., et al. Pentoxifylline inhibits lipopolysaccharide-induced serum tumor necrosis factor and mortality. Life Sci 1990, 47:1023-1029.
15. Tong Z., Chen B., Dai H., Bauer P.C., Guzman J., Costabel U. Extrinsic allergic alveolitis: inhibitory effects of pentoxifylline on cytokine production by alveolar macrophages. Ann Allergy Asthma Immunol 2004, 92:234-239.
16. Park M.K., Fontana, Babaali H., Gilbert-McClain L.I., Stylianou M., Joo J., et al. Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2009, 26(2):121-123.
17. Inoue K., Takano H., Yanagisawa R., Sakurai M. Anti-inflammatory effect of pentoxifylline. Chest 2004, 126(1):321.
18. Berman B., Wietzerbin J., Sanceau J., Merlin G., Duncan M.R. Pentoxifylline inhibits certain constitutive and tumor necrosis factor-alpha-induced activities of human normal dermal fibroblasts. J Invest Dermatol 1992, 98:706-712.
19. Fang C.C., Lai M.N., Chien C.T., Hung K.Y., Tsai C.C., Tsai T.J., et al. Effects of pentoxifylline on peritoneal fibroblasts and silica-induced peritoneal fibrosis. Perit Dial Int 2003, 23:228-236.
20. Romanelli R.G., Caligiuri A., Carloni V., DeFranco R., Montalto P., Ceni E., et al. Effect of pentoxifylline on the degradation of procollagen type I produced by human hepatic stellate cells in response to transforming growth factor-beta 1. Br J Pharmacol 1997, 122:1047-1054.
21. Cardoso C.C., Paviani E.R., Cruz L.A., Guma F.C., Borojevic R., Guaragna R.M. Effect of pentoxifylline on arachidonic acid metabolism, neutral lipid synthesis and accumulation during induction of the lipocyte phenotype by retinol in murine hepatic stellate cell. Mol Cell Biochem 2003, 254:37-46.
22. Valente E.G., Vernet D., Ferrini M.G., Qian A., Rajfer J., Gonzalez-Cadavid N.F. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. Nitric Oxide 2003, 9:229-244.
23. Cock A.M., Cano L.E., Vélez D., Aristizábal B., Trujillo J., Restrepo A. Fibrotic sequelae in pulmonary paracoccidioidomycosis: histopathological aspects in BALB/c mice infected with viable and non-viable propagules. Rev Inst Med Trop S Paulo 2000, 42:59-66.
24. Franco L., Najvar L., Gómez B., Restrepo S., Graybill J.R., Restrepo A. Experimental pulmonary fibrosis induced by Paracoccidioides brasiliensis conidia: measurement of the host local responses. Am J Tro Med Hyg 1998, 58:424-430.
25. McEwen J.G., Bedoya V., Patiño M.M., Salazar M.E., Restrepo A. Experimental murine Paracoccidioidomycosis induced by the inhalation of conidia. J Med Vev Mycol 1987, 25:165-175.
26. González A., Restrepo A., Cano L.E. Pulmonary immune responses induced in BALB/c mice by Paracoccidioides brasiliensis conidia. Mycopathologia 2008, 165(4-5):313-330.
27. González A., Sahaza J.H., Ortiz B.L., Restrepo A., Cano L.E. Production of pro-inflammatory cytokines during the early stages of experimental Paracoccidioides brasiliensis infection. Med Mycol 2003, 41(5):391-399.
28. Ostrosky-Zeichner L., Soto-Hernandez J.L., Angeles-Morales V., Teixeira F., Nava-Ruiz C., Rios C., et al. Effects of pentoxifylline or dexamethasone in combination with amphotericin B in experimental murine cerebral cryptococcosis: evidence of neuroexcitatory pathogenic mechanisms. Antimicrob Agents Chemother 1996, 40:1194-1197.
29. Sgonc R., Wick G. Pro- and anti-fibrotic effects of TGF-beta in scleroderma. Rheumatology (Oxford) 2008, 5(Suppl. 47):v5-v7.
30. Selman M., King T.E., Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001, 134:136-151.
31. Strieter R.M., Gomperts B.N., Keane M.P. The role of CXC chemokines in pulmonary fibrosis. J Clin Invest 2007, 117:549-556.
32. Restrepo A. Morphological aspects of Paracoccidioides brasiliensis in lymph nodes: implications for the prolonged latency of paracoccidioidomycosis?. Med Mycol 2000, 38:317-322.
33. González A., Aristizábal B.H., Caro E., Restrepo A., Cano L.E. TNF-α-activated macrophages inhibit transition of Paracoccidioides brasiliensis conidia to yeast cells through a mechanism independent of nitric oxide. J Trop Med Hyg 2004, 71:828-830.
34. Phillips K., Weinblatt M. Granulomatous lung disease occurring during etanercept treatment. Arthritis Care Res 2005, 53:618-620.
35. Wynn T.A. Cellular and molecular mechanisms of fibrosis. J Pathol 2008, 214(2):199-210.
36. Collard H.R., King T.E., Bartelson B.B., Vourlekis J.S., Schwarz M.I., Brown K.K. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003, 168:538-542.
37. Tamagawa K., Taooka Y., Maeda A., Hiyama K., Ishioka S., Yamakido M. Inhibitory effects of a lecithinized superoxide dismutase on bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 2000, 161:1279-1284.
38. Entzian P., Zahringer U., Schlaak M., Gerlach C., Galle J., Zabel P. Comparative study on effects of pentoxifylline, prednisolone and colchicine in experimental alveolitis. Int J Immunopharmacol 1998, 20:723-735.
39. Bonniaud P., Margetts P.J., Ask K., Flanders K., Gauldie J., Kolb M. TGF-beta and Smad3 signaling link inflammation to chronic fibrogenesis. J Immunol 2005, 175:5390-5395.
40. Kaviratne M., Hesse M., Leusink M., Cheever A.W., Davies S.J., McKerrow J.H., et al. IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent. J Immunol 2004, 173:4020-4029.
41. Loures F.V., Pina A., Felonato M., Calich V.L. TLR2 is a negative regulator of Th17 cells and tissue pathology in a pulmonary model of fungal infection. J Immunol 2009, 183:1279-1290.
42. Acosta-Rodriguez E.V., Rivino L., Gejinat J., Jarrossay D., Gattorno M., Lanzavechia A., et al. Surface phenotype and antigenic specificity of human inteleukin 17-producing T helper memory cells. Nat Immunol 2007, 8:639-642.
43. Cavassani K.A., Campanelli A.P., Moreira A.P., Vancim J.O., Vitali L.H., Mamede R.C., et al. Systemic and local characterization of regulatory T cells in a chronic fungal infection in humans. J Immunol 2007, 177:5811-5818.
44. Loures F.V., Pina A., Felonato M., Araújo E.F., Leite K.R., Calich V.L. Toll-Like receptor 4 signaling leads to severe fungal infection associated with enhanced proinflammatory immunity and impaired expansion of regulatory t cells. Infect Immun 2010, 78:1078-1088.
45. Berman B., Duncan M.R. Pentoxifylline inhibits the proliferation of human fibroblasts derived from keloid, scleroderma and morphoea skin and their production of collagen, glycosaminoglycans and fibronectin. Br J Dermatol 1990, 123:339-346.
46. Desmouliere A., Xu G., Costa A.M., Yousef I.M., Gabbiani G., Tuchweber B. Effect of pentoxifylline on early proliferation and phenotypic modulation of fibrogenic cells in two rat models of liver fibrosis and on cultured hepatic stellate cells. J Hepatol 1999, 30:621-631.
47. Pawlik M.T., Schreyer A.G., Ittner K.P., Selig C., Gruber M., Feuerbach S., et al. Early treatment with pentoxifylline reduces lung injury induced by acid aspiration in rats. Chest 2005, 127:613-621.
48. Rajendran R., Rani V., Shaikh S. Pentoxifylline therapy: a new adjunct in the treatment of oral submucous fibrosis. Indian J Dent Res 2006, 17:190-198.
49. Strutz F., Heeg M., Kochsiek T., Siemers G., Zeisberg M., Muller G.A. Effects of pentoxifylline, pentifylline and gamma-interferon on proliferation, differentiation, and matrix synthesis of human renal fibroblasts. Nephrol Dial Transplant 2000, 15:1535-1546.
50. Toda K., Kumagai N., Kaneko F., Tsunematsu S., Tsuchimoto K., Saito H., et al. Pentoxifylline prevents pig serum-induced rat liver fibrosis by inhibiting interleukin-6 production. J Gastroenterol Hepatol 2009, 24:860-865.